negative control recombinant human cripto 1 r d minneapolis mn (R&D Systems Hematology)
Structured Review
Negative Control Recombinant Human Cripto 1 R D Minneapolis Mn, supplied by R&D Systems Hematology, used in various techniques. Bioz Stars score: 90/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+human+cripto/Recombinant+Human+Cripto-1+Protein/pm26327334-50-9-14
Average 90 stars, based on 2 article reviews
Images
Related Articles
Negative Control:Article Title: Cripto-1: an extracellular protein - connecting the sequestered biological dots. Article Snippet: Cripto-1 (CR-1) is a multifunctional embryonic protein that is re-expressed during inflammation, wound repair, and malignant transformation.. CR-1 can function either as a tethered co-receptor or shed as a free ligand underpinning its flexible role in cell physiology.. CR-1 has been shown to mediate cell growth, migration, invasion, and induce epithelial to mesenchymal transition (EMT). Recombinant:Article Title: Cripto-1: an extracellular protein - connecting the sequestered biological dots. Article Snippet: Cripto-1 (CR-1) is a multifunctional embryonic protein that is re-expressed during inflammation, wound repair, and malignant transformation.. CR-1 can function either as a tethered co-receptor or shed as a free ligand underpinning its flexible role in cell physiology.. CR-1 has been shown to mediate cell growth, migration, invasion, and induce epithelial to mesenchymal transition (EMT). Incubation:Article Title: Cripto-1: an extracellular protein - connecting the sequestered biological dots. Article Snippet: Cripto-1 (CR-1) is a multifunctional embryonic protein that is re-expressed during inflammation, wound repair, and malignant transformation.. CR-1 can function either as a tethered co-receptor or shed as a free ligand underpinning its flexible role in cell physiology.. CR-1 has been shown to mediate cell growth, migration, invasion, and induce epithelial to mesenchymal transition (EMT). Control:Article Title: Differentiating ES cells using a tenascin Article Snippet: .. To each well, 7.5 μl of diluted factor was added from the working stock solutions to obtain the following final concentrations: VEGF-A (165 kDa) (R&D Biosystems cat #293VE) was used at 20 ng/mL, LAP (R&D #246-LP) at 50 ng/mL, Flt-3/Flk-2 ligand (R&D #308-FK) at 5 ng/mL, TGF beta-1 (R&D #240-B) at 0.1 ng/mL, IGF-1 (R&D #291-G1) at 10 ng/mL, PIGF (R&D #264-PG) at 20 ng/mL, Tie-1/Fc chimera (R&D #619-TI) at 100 ng/mL, BMP-2 (R&D #355-BM) at 500 ng/mL, BMP-4 (R&D #314-BP) at 250 ng/mL, BMP-5 (R&D #615-BM) at 2 μg/mL, FGF-17 (R&D #319-FG) at 50 ng/mL, TGF-alpha (R&D #239-A) at 0.5 ng/mL, Fibronectin (human 120 chymotryptic fragment, Gibco #12159-018) at 50 ng/mL, Merosin (Gibco #12162-012) at 50 ng/mL, Tenascin (Gibco #12175-014) at 50 ng/ml, IL-1-alpha (R&D #200-LA) at 10 μg/mL, FGF-4 (R&D #235-F4) at 0.25 ng/mL, SCF (R&D #255-SC) at 10 ng/mL, bFGF (R&D #233-FB) at 1.0 ng/mL, PDGF (R&D #120-HD) at 5.0 ng/mL, PECAM-1 (R&D #ADP6) at 1.0 μg/mL, anti-FGF-4 antibody (R&D #AF235) at 0.5 μg/mL, |
